Methods for detecting, identifying, and/or quantifying a target molecule in a complex fluid using thermal analysis are disclosed. Exemplary complex fluids include biofluids and environmental fluids. Exemplary target molecules include proteins, peptides, nucleic acids, lipids, carbohydrates, viruses, and combinations thereof. A method for using thermal analysis to determine whether purification affects one or more characteristics, such as binding characteristics, of a target molecule is also disclosed.

This document provides methods and materials related to genetic variations of developmental disorders.

For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.

Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.

The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.

The present application provides use of a CCDC157 gene and mutant genes thereof as molecular markers in diagnosis of male infertility diseases. Experiments have shown that the CCDC157-MIF515 mutant gene/protein causes male infertility, spermatogenesis disorder, sperm dysfunction, reduced sperm count, reduced sperm motility, abnormal sperm morphology, abnormal sperm head, etc. The CCDC157-MIF515 mutant gene/protein of the present application can be used as target genes for diagnosing male infertility. Meanwhile, the expression level of the CCDC157 of CCDC157 gene/protein is significantly reduced in NOA patients and SCOS patients, and the male infertility can be prevented and/or treated by increasing the activity and/or expression of the CCDC157 protein.

The present invention relates to a method for screening pore-forming membrane proteins, membrane transporters and molecular switches. The invention also relates to a kit for carrying out the method.

The present disclosure relates to a composition for treating or diagnosing osteoarthritis targeting activin A receptor type 2B (ACVR2B). More specifically, the present disclosure provides ACVR2B as a biomarker for diagnosing osteoarthritis because it was found that expression and activity of ACVR2B were increased at an early stage of osteoarthritis, expression of Mmp3, Mmp13, and Cox2 that induce destruction of cartilage was increased thereby, and expression of the genes was suppressed by inhibition of ACVR2B expression. In addition, since it was found that osteoarthritis was alleviated by suppressing the expression of ACVR2B, the present disclosure provides an ACVR2B expression or activity inhibitor as a therapeutic agent for osteoarthritis.

The invention relates to using cell free nucleosome levels to identify patients at risk of developing a NETosis associated adverse reaction to the infection. The methods are used to monitor the progress of a disease and assigning a risk of an adverse outcome in a patient suffering from an infection.

The present invention relates to the identification and use of markers indicative for the response of a subject to immunotherapy as anti-cancer treatment. The markers are particularly useful in predicting response of a subject to immunotherapy with PD-1 or PD-L1 antagonists in the treatment of cancer. PD-1 and PD-L1 antagonists are typically used as immunotherapy in the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), and squamous cell carcinoma.

The disclosure pertains to conformational epitopes in alpha-synuclein, antibodies thereto and methods of making and using immunogens and antibodies specific thereto. In particular antibodies raised to cyclic compounds comprising at least 3 amino acids of EKTKEQ (SEQ ID NO: 1) selectively recognize misfolded oligomeric alpha-synuclein and are able to inhibit alpha-synuclein propagation and toxicity.